ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

In LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleonucleotides Results in Compensatory Changes in Apoptosis

Journal: Scientific Journal of Genetics and Gene Therapy (Vol.1, No. 1)

Publication Date:

Authors : ; ;

Page : 001-006

Keywords : Antisense oligonucleotides; Prostate cancer; BCL-2; bax; caspase-3; clusterin; AKT-1; Therapy;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Antisense oligonucleotides (oligos) have been evaluated for treating prostate cancer in both in vivo and in vitro models. Although most oligos contain a single mRNA binding site, our laboratory evaluates bi-specific oligos directed towards two proteins. This study evaluates the growth inhibition in vitro of the LNCaP cell line employing mono- and bispecific oligos directed against BCL-2 [the second binding site was directed against the epidermal growth factor receptor (EGFR)]. These oligos were administered with lipofectin as part of a nanoparticle delivery system. Additionally, g, the expression of five apoptosis regulatory proteins, BCL-2, bax, caspase-3, clusterin and AKT-1 was evaluated by RTPCR.

Last modified: 2019-04-25 21:39:04